Associations - Tabrecta (capmatinib)

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	capmatinib Sensitive: C2 – Inclusion Criteria capmatinib Sensitive : C2	capmatinib Sensitive: C2 – Inclusion Criteria capmatinib Sensitive : C2
EGFR T790M + MET positive	Non Small Cell Lung Cancer	EGFR T790M + MET positive	Non Small Cell Lung Cancer	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3
MET positive + EGFR mutation	Non Small Cell Lung Cancer	MET positive + EGFR mutation	Non Small Cell Lung Cancer	erlotinib + capmatinib Sensitive: C3 – Early Trials erlotinib + capmatinib Sensitive : C3	erlotinib + capmatinib Sensitive: C3 – Early Trials erlotinib + capmatinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	gefitinib + capmatinib Sensitive: C3 – Early Trials gefitinib + capmatinib Sensitive : C3	gefitinib + capmatinib Sensitive: C3 – Early Trials gefitinib + capmatinib Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + capmatinib Resistant: C3 – Early Trials pembrolizumab + capmatinib Resistant : C3	pembrolizumab + capmatinib Resistant: C3 – Early Trials pembrolizumab + capmatinib Resistant : C3
MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: C3 – Early Trials capmatinib Sensitive : C3	capmatinib Sensitive: C3 – Early Trials capmatinib Sensitive : C3
MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3
MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3	capmatinib + PDR001 Sensitive: C3 – Early Trials capmatinib + PDR001 Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + capmatinib Sensitive: C3 – Early Trials osimertinib + capmatinib Sensitive : C3	osimertinib + capmatinib Sensitive: C3 – Early Trials osimertinib + capmatinib Sensitive : C3
KIAA1549-BRAF fusion + MET amplification	Non Small Cell Lung Cancer	KIAA1549-BRAF fusion + MET amplification	Non Small Cell Lung Cancer	trametinib + dabrafenib + capmatinib Sensitive: C4 – Case Studies trametinib + dabrafenib + capmatinib Sensitive : C4	trametinib + dabrafenib + capmatinib Sensitive: C4 – Case Studies trametinib + dabrafenib + capmatinib Sensitive : C4
MET amplification	Cholangiocarcinoma	MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4
EGFR mutation + MET Y1003N	Non Small Cell Lung Cancer	EGFR mutation + MET Y1003N	Non Small Cell Lung Cancer	osimertinib + capmatinib Sensitive: C4 – Case Studies osimertinib + capmatinib Sensitive : C4	osimertinib + capmatinib Sensitive: C4 – Case Studies osimertinib + capmatinib Sensitive : C4
KIF5B-MET fusion	Non Small Cell Lung Cancer	KIF5B-MET fusion	Non Small Cell Lung Cancer	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4
EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	erlotinib + capmatinib Sensitive: C4 – Case Studies erlotinib + capmatinib Sensitive : C4	erlotinib + capmatinib Sensitive: C4 – Case Studies erlotinib + capmatinib Sensitive : C4
MET amplification + MET overexpression	Non Small Cell Lung Cancer	MET amplification + MET overexpression	Non Small Cell Lung Cancer	capmatinib Resistant: C4 – Case Studies capmatinib Resistant : C4	capmatinib Resistant: C4 – Case Studies capmatinib Resistant : C4
CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4	capmatinib Sensitive: C4 – Case Studies capmatinib Sensitive : C4
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	alectinib + capmatinib Sensitive: C4 – Case Studies alectinib + capmatinib Sensitive : C4	alectinib + capmatinib Sensitive: C4 – Case Studies alectinib + capmatinib Sensitive : C4
ALK rearrangement + MET amplification	Non Small Cell Lung Cancer	ALK rearrangement + MET amplification	Non Small Cell Lung Cancer	alectinib + capmatinib Sensitive: C4 – Case Studies alectinib + capmatinib Sensitive : C4	alectinib + capmatinib Sensitive: C4 – Case Studies alectinib + capmatinib Sensitive : C4
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	savolitinib + capmatinib Sensitive: D – Preclinical savolitinib + capmatinib Sensitive : D	savolitinib + capmatinib Sensitive: D – Preclinical savolitinib + capmatinib Sensitive : D
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: D – Preclinical capmatinib Sensitive : D	capmatinib Sensitive: D – Preclinical capmatinib Sensitive : D

Tabrecta (capmatinib)

Associations
(23)

Associations
(23)

Tabrecta (capmatinib)

Associations(23)

Associations(23)

Associations
(23)

Associations
(23)